Tempus AI will continue its acquisitive streak after closing a mostly stock deal for digital pathology company Paige, CEO Eric Lefkofsky tells Axios Pro.
Why it matters: As a downturn in biotech investing puts pressure on life sciences, more firms may seek lifelines from publicly traded enterprises like Tempus.
